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Abstract 
Background: Maternal microchimerism (MMc), the transmission of small quantities 
of maternal cells to the fetus, is relatively common and persistent. MMc has been 
detected with increased frequency in the circulation and pancreas of type 1 diabetes 
(T1D) patients. We investigated for the first time whether MMc levels at birth predict 
future T1D risk. We also tested whether cord blood MMc predicted MMc in samples 
taken at T1D diagnosis.  
Methods: Participants in the Norwegian Mother and Child Cohort study were HLA 
class II typed to determine non-inherited, non-shared maternal alleles (NIMA). 
Droplet digital (dd) PCR assays specific for common HLA class II NIMA 
(HLADQB1*03:01, *04:02 and *06:02/03) were developed and validated. MMc was 
estimated as maternal DNA quantity in the fetal circulation, by NIMA specific ddPCR, 
measured in cord blood DNA from 71 children who later developed T1D and 126 
controls within the cohort.  
Results: We found detectable quantities of MMc in 34/71 future T1D cases (48%) 
and 53/126 controls (42%) (adjusted odds ratio (aOR) 1.27, 95%CI 0.68-2.36), and 
no significant difference in ranks of MMc quantities between cases and controls 
(Mann-Whitney P=0.46). There was a possible association in the NIMA HLA-
DQB1*03:01 subgroup with later T1D (aOR 3.89, 95%CI 1.05-14.4). MMc in cord 
blood was not significantly associated with MMc at T1D diagnosis.  
Conclusions: Our findings did not support the hypothesis that the degree of MMc in 
cord blood predict T1D risk. The potential subgroup association with T1D risk should 
be replicated in a larger cohort.  
 
Keywords: Microchimerism, HLA, Type 1 diabetes, Pregnancy, Childhood   
This article is protected by copyright. All rights reserved.
Introduction 
Type 1 diabetes (T1D) is an autoimmune disease where insulin-producing beta cells 
become targeted by the immune system. The main known genetic risk factor for T1D 
is HLA genotype, and many weaker genetic risk factors exist1. Environmental factors 
are not well characterized, but it has been hypothesized that prenatal and early life 
factors influence T1D risk2,3.  
 
Maternal transmission of cells to the fetus during pregnancy, known as maternal 
microchimerism (MMc), is believed to protect against fetal loss4, and promote 
regulatory T cell mediated tolerance against non-inherited maternal antigens5. MMc 
has been shown to persist into adult life6, is relatively common7, and has been 
associated with both protective and adverse effects8,9. MMc has been postulated to 
play a role in autoimmune diseases, where it could be particularly relevant due to the 
strong association between certain HLA genotypes and autoimmune diseases8. MMc 
can be detected or quantified by targeting non-inherited, non-shared maternal allele 
(NIMA) DNA originating from maternal cells. 
 
MMc has been detected in several tissues, amongst them islet beta cells10 in the 
pancreas, with increased frequency of MMc in T1D patients11. Higher levels of MMc 
in the circulation have also been shown for patients with T1D compared with healthy 
controls, using a quantitative PCR approach to detect non-inherited HLA alleles10. 
This increase could be due to MMc being present before development of T1D, or 
expansion of existing cells as a result of disease development. No studies to date 
however have investigated whether those who later develop disease have higher 
MMc levels prior to disease onset. Although the biological functions of MMc are 
largely unknown, we hypothesized that higher levels of pre-diagnostic MMc would 
contribute to lower risk of T1D. 
 
Since MMc likely results from transplacental transfer via cord blood, we developed 
sensitive allele specific ddPCR assays to test for the first time whether cord blood 
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MMc have any predictive value for childhood-onset T1D. Secondly, we investigated 
whether cord blood MMc predicted circulating MMc at diagnosis of T1D.   
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Research Design and Methods 
 
Participants 
We designed a nested case-control study in the Norwegian Mother and Child Cohort 
Study (MoBa)12, which recruited around 114,000 children and their mothers (41% of 
eligible mothers participated) from all over Norway during 1999-2008. The current 
study uses data from repeated questionnaires, maternal postpartum and offspring 
cord blood samples13. All study participants gave written informed consent. The 
Norwegian Data Protection Authority and The Regional Committee for Medical 
Research Ethics approved MoBa and the current study. Characteristics of the 
participants are shown in Table 1. Baseline characteristics for those with available 
blood samples were largely similar to the whole MoBa cohort, except a lower 
proportion of caesarean section and premature birth (see 14). 
 
Ascertainment of case status 
Children who developed T1D by February 5, 2014 were identified with a high degree 
of ascertainment by register linkage to the Norwegian Childhood Diabetes Registry15 
and used as cases. A random set of controls was selected among participants in the 
MoBa cohort with available blood samples. We later ascertained if the initially 
selected random controls developed T1D until 1 June 2018. In total, 186 
mother/child-pairs where the child developed T1D and 540 mother/child-pairs were 
used as controls. Of these, 71 T1D cases and 126 controls had an informative HLA 
for the NIMA ddPCR assays available: DQB1*03:01, *04:02, or *06:02/03 (Figure 1).  
 
Sampling 
Briefly, maternal venous blood samples were collected in EDTA tubes during 
pregnancy and shortly after birth, and a blood sample was taken at birth from the 
umbilical cord vein using a syringe12,13,16. At diagnosis of T1D, venous blood samples 
were collected and shipped to the Norwegian Childhood Diabetes Registry. At the 
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biobank repository, DNA was extracted and stored at -20°C until analysis. For details 
of sample handling, see 13,16,17. 
 
Genotyping 
To account for established T1D susceptibility markers, participants were genotyped 
using a custom Illumina Golden Gate assay (Illumina, San Diego, CA). DNA 
extraction, genotyping methods and quality control procedures are described in detail 
in a previous publication18. Briefly, tag-SNPs (n = 144) on chromosome 6 were used 
to impute human leukocyte antigen (HLA) class II genotype19, which was 
subsequently confirmed by classical HLA genotyping using allele specific PCR on all 
samples20. For each informative dyad, we inferred the non-inherited non-shared HLA-
DQB1 allele, NIMA (Figure 1, panel A).  
 
Droplet Digital (dd)PCR MMc quantification 
MMc were measured by quantifying the amount of NIMA specific DNA in cord blood. 
We developed allele-specific ddPCR assays for three common NIMAs (DQB1*03:01, 
DQB1*04:02, DQB1*06:02/*06:03), based on previous quantitative PCR assays10,21, 
to improve sensitivity for low copy number targets. A detailed protocol for the ddPCR 
method is available upon request. We used the droplet digital PCR QX200 system 
(Bio-Rad, California, USA). Final primer and probe concentrations optimized for 
DQB1*04:02 and DQB1*06:02/03 at 100nM and 300nM, and DQB1*03:01 at 300nM 
and 100nM respectively. DNA was quantified using the QuantiFluor dsDNA system 
(Promega, Madison, USA). Supplementary figure 1 shows the ddPCR profiles of a 
negative, genomic positive and positive cord blood sample for MMc DQB1*0602/3. 
 
Sensitivity of assays determined using serial dilutions (500, 100, 5, 1 and 0.5 
genomic equivalent (gEq)) of NIMA positive homozygous DNA in a background DNA 
quantity of 10,000 genome equivalent negative for NIMA. Specificity for each assay 
was determined using well-characterized HLA cell lines. Ten wells were run for each 
sample, loaded at 10,000 gEq equal to 33ng; 100,000 gEq was screened per 
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sample. MMc value was determined by total copy number of HLA allele specific 
positive cells per 1 000 000 host cells as determined by beta-globin. 
A priori, we decided to consider a sample positive only if two or more of the 10 
replicates were positive. Samples with only one positive well (n = 62) were set to an 
MMc value of zero. Figure 1B shows the formation of the analysis sample.  
 
As the measured MMc levels between probes are not directly comparable, we 
calculated MMc z-scores by subtracting the NIMA specific mean and dividing by the 
standard deviation (both calculated from control children), all done on 
log2transformed raw values. 
 
Other covariates 
A priori, we chose maternal pre-pregnancy body mass index (BMI) and maternal age 
as our primary adjusting variables, as these have been associated with T1D22-24 and 
could conceivably influence MMc. In a separate model we further included maternal 
smoking during pregnancy25 (coded as smoking or non-smoking at end of 
pregnancy), caesarean section26 and child`s HLA risk for T1D (coded as a binary 
variable; protective or neutral vs increased risk) as a sensitivity analysis. Distribution 
of these covariates are presented in Table 1. 
 
Maternal age at delivery was obtained from the nationwide Medical Birth Registry of 
Norway (MBRN). Information regarding maternal pre-pregnancy BMI was obtained 
from mid-pregnancy questionnaires (accessible at www.fhi.no/moba) and MBRN.  
 
Statistical analysis 
We tested maternal microchimerism as a dichotomous variable (positive vs negative) 
and divided into three categories (negative, ≤median of quantifiable MMc values, 
>median of the quantifiable MMc values), using logistic regression. We also tested 
whether the ranks of MMc differed between cases and controls using a Mann-
Whitney U test. In a secondary analysis, we stratified the above analysis by specific 
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NIMA alleles. The statistical association between MMc in cord blood and at diagnosis 
of T1D in the same individual cases was estimated using logistic regression (for 
presence or absence of measurable MMc). To assess the sensitivity of our results 
towards the cut-off for MMc positivity, we reran the analysis when also calling 
samples positive if only one of 10 replicates were positive. All analyses were done in 
Stata Release 15 (College Station, Tx, USA).  
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Results 
Out of 726 genotyped mother-child dyads, 197 (71 T1D cases and 126 controls) 
provided data for the analysis (Figure 1). Of the 71 cases, a sample at the time of 
T1D diagnosis with valid MMc data was available from 60. We measured a positive 
MMc value in 87/197 samples (44%). The quantities measured in this study are 
shown Table 1. 
 
Differences between cases and controls 
Having any detectable MMc in cord blood was not significantly associated with later 
T1D (aOR 1.27, 95% CI 0.68-2.36, p=0.45). Investigating specific NIMAs, MMc 
tended to be associated with increased risk for later T1D in the group with HLA-
DQB1*03:01 as the NIMA (Table 2). Investigating MMc quantity divided into three 
groups (no detectable NIMA vs. below or at median, and above median) gave similar 
results, with showed no significant associations with T1D overall, and a suggestive 
positive association for those with HLA-DQB1*03:01 as the NIMA (Table 2). 
 
Comparing the ranks of the levels measured did not show any significant difference 
between cases and controls when summing all NIMAs (Mann-Whitney P = 0.46), or 
in specific alleles (Mann-Whitney P = 0.07 and 0.77 for HLA DQB1*03:01 and 
*06:02/03, respectively). 
 
Association between presence of MMc at birth and diagnosis 
There was a tendency for presence of MMc in cord blood to be associated with 
detectable MMc levels in the circulation at diagnosis of T1D (at an average of 6.1 




Including more covariates, or changing the cut-off for positive MMc generally resulted 
in wider confidence intervals, but odds ratios were largely similar (Table 3).  
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Discussion 
In this first study of its kind, we tested whether cord blood MMc at birth was 
informative of future T1D risk, but we found no significant overall association.   
 
An important strength of this study was the use of digital droplet PCR, which allowed 
us to investigate the presence of MMc in a more sensitive and specific manner than 
earlier studies. We observed more children with detectable MMc than a previous 
study from Korea (44% in our study vs 23%), but we use ddPCR which is considered 
a more sensitive method. Earlier studies in T1D have investigated individuals after 
diagnosis in peripheral blood and pancreatic tissue10,11. Our results are not consistent 
with results from these, which could be due to MMc differences between cord blood 
at birth, and in the pancreas or circulation, as we found no increased risk associated 
with the presence, or levels, of total MMc. We found a possible association in the 
HLA-DQB1*03:01 NIMA subgroup with later T1D, which must be interpreted with 
caution. 
  
While maternal cells are believed to cross into the fetus through the umbilical cord, 
with increased frequency from mid pregnancy towards term, it is only feasible to 
measure MMc levels on the day of delivery. In theory, transfer of cells could fluctuate 
temporally. Our study does not rule out an important role of MMc in T1D, for example 
in terms of specific cell types or their functions in specific tissues postnatally10,11. This 
is an observational study, and we cannot rule out unknown factors influencing MMc 
levels and later disease. Although the current analysis emanate from a large 
undertaking, the number of children with informative and measurable MMc in the final 
analysis was somewhat limited. Because of the strong protective effect of 
DQB1*06:02, this allele is known to be relatively over-represented as the NIMA in 
T1D cases but the data presented here suggest that this allele does not confer any 
additional protective effect through MMc. 
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In conclusion, our findings do not support a protective role of pre-diagnostic MMc in 
T1D, as maternal microchimerism measured in cord blood did not significantly predict 
the risk of future T1D in children.  
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Table 1: Characteristics of cases with childhood type 1 diabetes and randomly 
selected controls in the present study. 
 Cases (n = 71) Controls (n= 126) 
Median age (range) at end of follow-up* (years) 11.5 (7.3 – 15.1) 10.5 (7.0 – 15.9)  
Female sex 34 (47.9%) 64 (50.8%) 
Preterm birth 5 (7.0%) 4 (3.2%) 
Parity   
No earlier births 35 (49.3%) 60 (47.6%) 
One 20 (28.2%) 40 (31.7%) 
Two or more 16 (22.5%) 26 (20.6%) 
Maternal age (years (median, range)) 30 (22 – 42) 30 (19 – 40) 
19-24 4 (5.6%) 17 (13.5%) 
25-34 55 (77.5%) 86 (68.3%) 
35-42 12 (16.9%) 23 (18.3%) 
Maternal smoking during pregnancy   
Non-smoker at end of pregnancy‡ 61 (85.9%) 104 (82.5%) 
Smoked at end of pregnancy 7 (9.9%) 17 (13.5%) 
Missing data 3 (4.2%) 5 (4.0%) 
Pre-pregnancy BMI (kg/m2(median, range)) 26.1 (17.3 – 38.6) 24.1 (18.7 – 37.8) 
<25 28 (39.4%) 67 (53.2%) 
25-30 27 (38.0%) 34 (27.0%) 
>30 10 (14.1%) 12 (9.5%) 
Missing data 6 (8.5%) 13 (10.3%) 
Child’s HLA genotype§   
Protective (DQ6) 2 (2.8%) 21 (16.7%) 
Neutral (any other HLA not mentioned) 3 (4.2%) 29 (23.0%) 
Increased risk (≥1 copy of either DQ8 or DQ2.5) 38 (53.5%) 68 (54.0%) 
High risk (DQ8/DQ2.5 heterozygote) 28 (39.4%) 8 (6.3%) 
Caesarean section|| 8 (10.8%) 15 (11.2%) 
MMc quantities (median (range)¶)   
DQB1*03:01 NIMA in cord blood  55.4 (10.9 – 867.7) 46.8 (16.7 – 588.8)  
DQB1*03:01 NIMA at diagnosis 43.5 (10.0 – 221.2)   
DQB1*04:02 NIMA in cord blood 65.0 (16.8 – 76.6) 17.2 (16.2 – 144.8)  
DQB1*04:02 NIMA at diagnosis 50.3 (16.8 – 59.2)   
DQB1*06:02/3 NIMA in cord blood 30.9 (15.2 – 343.8) 48.6 (9.5 – 1010.2)  
DQB1*06:02/3 NIMA at diagnosis 55.8 (13.2 – 190.4)   
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* The diagnosis date of the last case included - June 2, 2016 
† The median age at diagnosis of T1D cases was 6.3 (range 0.7 – 13.0) years  
‡ Including those that quit smoking shortly before or during pregnancy, as the association 
with T1D has been observed in those that smoked throughout pregnancy 25. 
§ Coded as a binary variable in the analysis – protective or neutral (0) vs increased or high 
risk (1). The increased risk category (≥1 copy of either DQ8 [DQA1*03-DQB1*03:02-
DRB1*04] or DQ2.5 [DQA1*05:01-DQB1*02:01] also required no HLA DQ6 [DQA1*01:02-
DQB1*06:02-DRB1*15:01] protective allele).  
|| Includes unknown (n = 1), emergency (n = 9) and elective (n = 13) caesarean section 
¶ Median and range of positive values.  
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Table 2: Association between MMc in cord blood and type 1 diabetes 
 Cases† Controls† OR (95% CI) aOR (95% CI)* Adjusted 
P-value 
Presence of detectable MMc      
Any‡ NIMA 32/65 49/113 1.27 (0.71 - 2.27) 1.27 (0.68 - 2.36) 0.45 
    DQB1*03:01 NIMA 14/20 16/36 2.44 (0.81 - 7.35) 3.89 (1.05 - 14.44) 0.04 
    DQB1*06:02/03 NIMA 15/33 64/64 1.04 (0.47 - 2.31) 0.96 (0.40 - 2.27) 0.92 
Categorical analysis§      
Any‡ NIMA, Undetected 33/65 64/113 Ref. Ref.  
Any‡ NIMA ≤ median 18/65 26/113 1.52 (0.75 – 3.07) 1.34 (0.64 – 2.81) 0.44 
Any‡ NIMA > median 14/65 23/113 1.02 (0.48 – 2.18) 1.20 (0.54 – 2.65) 0.66 
Per category increase 65/65 113/113 1.07 (0.74 - 1.53) 1.12 (0.76 - 1.65) 0.56 
    DQB1*03:01 NIMA, undetected  6/20 20/36 Ref. Ref.  
    DQB1*03:01 NIMA ≤ median 6/20 9/36 2.10 (0.55 – 7.99) 2.74 (0.61 – 12.44) 0.19 
    DQB1*03:01 NIMA > median 8/20 7/36 2.79 (0.78 – 10.01) 5.77 (1.21 – 27.52) 0.03 
    Per category increase  20/20 36/36 1.68 (0.89 - 3.17) 2.40 (1.10 - 5.24) 0.03 
    DQB1*06:02/03 NIMA, undetected 18/33 35/64 Ref. Ref.  
    DQB1*06:02/03 NIMA ≤ median 11/33 15/64 1.65 (0.66 – 4.11) 1.36 (0.52 – 3.62) 0.54 
    DQB1*06:02/03 NIMA > median 4/33 14/64 0.48 (0.14 – 1.61) 0.51 (0.14 – 1.83) 0.30 
    Per category increase 33/33 64/64 0.82 (0.49 - 1.36) 0.80 (0.45 - 1.40) 0.43 
 
OR: Odds Ratio; aOR: adjusted OR; CI: Confidence Interval 
* adjusted for maternal age and pre-pregnancy BMI 
† included in the adjusted analysis. There were 71 cases and 126 controls in total in 
the unadjusted analyses.  
‡ combining DQB1*03:01, *04:02 and *06:02/03. The DQB1*04:02 NIMA subgroup 
was not analyzed separately due to low number of children with measurable 
quantities in this group.   
§ the median value was calculated from controls with detectable levels 
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Table 3: Sensitivity analyses 
 aOR (95% CI)*, 
Main analysis 
aOR (95% CI)†, 
additionally adjusted 
aOR (95% CI)*, including 
unreplicated positives 
Presence of detectable MMc    
Any‡ NIMA 1.27 (0.68 – 2.36) 1.28 (0.65 – 2.52) 1.19 (0.62 – 2.27) 
    DQB1*03:01 NIMA 3.89 (1.05 – 14.44) 6.33 (0.79 – 50.75) 2.39 (0.56 – 10.26) 
    DQB1*06:02/03 NIMA 0.96 (0.40 – 2.27) 1.05 (0.42 – 2.65) 1.26 (0.49 – 3.20) 
Categorical analysis§    
Any‡ NIMA, Undetected Ref. Ref. Ref. 
Any‡ NIMA ≤ median 1.34 (0.64 – 2.81) 1.42 (0.63 – 3.20) 0.75 (0.33 – 1.69) 
Any‡ NIMA > median 1.20 (0.54 – 2.65) 1.12 (0.47 – 2.69) 1.35 (0.80 – 3.40) 
Per category increase 1.12 (0.76 – 1.65) 1.10 (0.72 – 1.68) 1.29 (0.89 – 1.87) 
    DQB1*03:01 NIMA, undetected  Ref. Ref. Ref. 
    DQB1*03:01 NIMA ≤ median 2.74 (0.61 – 12.44) 5.99 (0.51 – 70.90) 0.83 (0.13 – 5.14) 
    DQB1*03:01 NIMA > median 5.77 (1.21 – 27.52) 6.65 (0.61 – 72.76) 4.40 (0.91 – 21.30) 
    Per category increase  2.40 (1.10 – 5.24) 2.64 (0.81 – 8.68) 2.24 (1.01 – 4.97) 
    DQB1*06:02/03 NIMA, undetected Ref. Ref. Ref. 
    DQB1*06:02/03 NIMA ≤ median 1.36 (0.52 – 3.62) 1.64 (0.56 – 4.79) 1.20 (0.41 – 3.53) 
    DQB1*06:02/03 NIMA > median 0.51 (0.14 – 1.83) 0.50 (0.13 – 1.92) 1.31 (0.46 – 3.77) 
    Per category increase 0.80 (0.45 – 1.40) 0.82 (0.45 – 1.48) 1.17 (0.70 – 1.97) 
 
aOR: adjusted OR; CI: Confidence Interval.  
Main analysis is shown leftmost for comparison, followed by an analysis including 
more covariates, and an analysis including the measured values of samples which 
were positive in only one of ten replicates (originally set to zero in the main analysis). 
* adjusted for maternal age and pre-pregnancy BMI 
† adjusted for maternal age, pre-pregnancy BMI, sustained smoking during 
pregnancy, caesarean section, childs’ gender and HLA risk for T1D.  
‡ combining DQB1*03:01, *04:02 and *06:02/03. The DQB1*04:02 NIMA subgroup 
was not analysed separately due to low number of children with measurable 
quantities in this group.   
§ the median value was calculated from controls with detectable levels. 
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Figure 1: Study overview 
 
† Includes also dyads with a non-DQB1 NIMA (n = 42). 
‡ This group includes samples (n = 26) that were tested with an earlier version of the 
ddPCR DQB1*03:01 probe which turned out to interact with other alleles, and were 
excluded. It also includes samples not found or with insufficient DNA (n = 8), samples 
with genomic levels of MMc (n = 8) potentially caused by contamination from 
maternal blood and maternal samples included by mistake (n = 1).  
 
Figure 1 shows how the study design and distribution of participants: Panel A shows 
example HLA-DQB1 genotypes in mothers and offspring to illustrate whether a NIMA 
can be measured (informative NIMA), and the resulting NIMA used to measure MMc. 
Note that as HLA-DQB1*06:02 and *06:03 assay are considered one genotype in this 
study due to the assay used. NIMA was ascertained by comparing maternal and 
offspring genotypes. If the mother is homozygous, or if mother and child share both 
alleles, we are unable to measure MMc as we cannot determine NIMA and child’s 
genomic levels of the genotype would mask the maternal signal (non-informative 
MMc). If the NIMA is informative (child has a NIMA that would not be masked by its 
own genotype), only the most common NIMA with ddPCR assays available were 
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tested:  HLA-DQB1*03:01, *04:02 or *06:02/03; others are referred to as “other 
NIMA”. Panel B shows a Sankey diagram to illustrate how many dyads fall into each 
category in our cohort. Panel C shows a histogram of observed MMc values in cord 
blood (in a log2 scale), in cases and controls, with the median of the positive samples 
(calculated using values from controls only) marked with a dashed line, and number 
of negative values listed in the top right corner of each facet. The top facet shows the 
total of all measured MMc, while the lower panels show per HLA genotype (HLA-
DQB1*03:01, *04:02 and *06:02/03, in descending order).  
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